Focused On-demand Library for Origin recognition complex subunit 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O43929

UPID:

ORC4_HUMAN

Alternative names:

Alternative UPACC:

O43929; B7Z3D0; B7Z5F1; D3DP86; F5H069; Q96C42

Background:

Origin recognition complex subunit 4 plays a pivotal role in DNA replication initiation, binding replication origins in an ATP-dependent manner. It recognizes specific DNA sequences to assemble the pre-replication complex, crucial for DNA replication onset. This protein also interacts with histone marks H3K9me3, H3K27me3, and H4K20me3, indicating a nuanced role in chromatin organization and gene regulation.

Therapeutic significance:

Linked to Meier-Gorlin syndrome 2, a condition marked by growth retardation and skeletal anomalies, Origin recognition complex subunit 4's genetic variants underscore its clinical relevance. Understanding its role could open doors to potential therapeutic strategies, offering hope for targeted interventions in genetic disorders involving DNA replication and chromatin modifications.